Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 10/20 | 0.36 |
| ▸ | HRH2 | P25021 | 9/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26744659 | 0.96 | HRH2 (0.36) | HRH1HRH2MEN1KMT2AMAPK1 | |
| SCHEMBL20323689 | 0.89 | KDM1A (0.37) | HRH1MEN1KMT2AMAPK1RAB9A | |
| SCHEMBL26741730 | 0.88 | MEN1 (0.41) | HRH1HRH2MEN1KMT2ARAB9A | |
| SCHEMBL11569854 | 0.86 | — | — | |
| SCHEMBL29322718 | 0.86 | MAPK1 (0.40) | MAPK1RAB9ACYP2D6CYP2C19HRH3 | |
| SCHEMBL26741732 | 0.86 | HRH3 (0.46) | HRH1CYP2D6CYP2C19HRH3 | |
| SCHEMBL12448066 | 0.85 | MAPK1 (0.45) | HRH1HRH2MEN1KMT2AMAPK1 | |
| SCHEMBL29316649 | 0.84 | SIGMAR1 (0.40) | MEN1KMT2AMAPK1RAB9ACYP2D6 | |
| SCHEMBL10961176 | 0.84 | CYP2D6 (0.41) | HRH1MAPK1RAB9ACYP2D6CYP2C19 | |
| SCHEMBL20328704 | 0.84 | HRH3 (0.39) | MEN1KMT2ARAB9AHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2A1, BCL2L1, BCL3 | HRH1 3575/4885HRH2 3194/4885MEN1 2077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.